SVP & Corporate Controller (Interim CFO for a portion of 2019) · Vertex Pharmaceuticals Inc (VRTX)

Paul Silva

FY2019 is the first fiscal year CompBrief holds for Paul Silva as a named executive officer of Vertex Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$3,197,857

Salary $442,569Stock awards $1,895,084

7th of 8 named executive officers at Vertex Pharmaceuticals by FY2019 total.

8 named officers on file for Vertex Pharmaceuticals, FY2019

Paul Silva’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 4 equity grants, each cited to its filing
  • VRTX’s disclosed peer group of 12 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vertex Pharmaceuticals’s whole pay program stands against its peers

  • Vertex Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2020 (DEF 14A).

Free

Get Paul Silva’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Paul Silva compensation by year

Vertex Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Vertex Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019
Salary$442,569
Bonus$0
Stock awards$1,895,084
Option awards$468,803
Non-equity incentive$378,000
Pension and deferred compensation$0
All other$13,401
Total$3,197,857

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vertex Pharmaceuticals Inc DEF 14A filed April 28, 2020, accession 0001308179-20-000229, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vertex Pharmaceuticals Inc filed document, accession 0001308179-20-000229. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2020.

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
RSU5,000$1,094,750—
RSU3,160$691,882—
RSU2,917$638,677—
RSU2,814$616,125—
RSU2,813$615,906—
PSU2,110$461,985—
RSU2,108$461,547—
RSU2,107$461,328—
RSU1,459$319,448—
PSU1,459$319,448—
Option1,290—$91.05
Option5,503—$155.57

Per the Outstanding Equity Awards at Fiscal Year-End table in Vertex Pharmaceuticals Inc's FY2019 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 15 award rows shown.

Vertex Pharmaceuticals’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Jeffrey LeidenExecutive Chairman (CEO and President through March 31, 2020)$18,789,985
Stuart ArbuckleEVP & Chief Commercial Officer$6,859,533
Reshma KewalramaniCEO and President (EVP & Chief Medical Officer through March 31, 2020)$6,816,936
Amit SachdevEVP & Chief Patient Officer$6,197,053
Michael PariniEVP & Chief Administrative, Legal and Business Development Officer$6,039,497
Charles WagnerEVP & Chief Financial Officer$3,487,213
Paul Silva · this pageSVP & Corporate Controller (Interim CFO for a portion of 2019)$3,197,857
Ian SmithFormer EVP & Chief Operating Officer and Former Interim Chief Financial Officer$1,451,840

The full Vertex Pharmaceuticals compensation record

free company brief

This page is one person within Vertex Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vertex Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vertex Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Paul Silva's compensation dossier · One-time report. No refunds.